Yayın:
Efficacy and safety of pembrolizumab in relapsed/refractory primary mediastinal large B‐cell lymphoma (rrPMBCL): interim analysis of the KEYNOTE‐170 phase 2 trial

Sadeleştirilmiş öğe sayfası
dc.contributor.authorGülbaş, Zafer
dc.contributor.authorCatherine Thiéblemont
dc.contributor.authorВ Я Мельниченко
dc.contributor.authorDzhelil Osmanov
dc.contributor.authorKrimo Bouabdallah
dc.contributor.authorJan Walewski
dc.contributor.authorAlejandro Majlis
dc.contributor.authorLaura Maria Fogliatto
dc.contributor.authorM. D. Caballero Barrigón
dc.contributor.authorChristian Bach
dc.contributor.authorZafer Gülbaş
dc.contributor.authorMuhi̇t Özcan
dc.contributor.authorGilles Salles
dc.contributor.authorMargaret A. Shipp
dc.contributor.authorArun Balakumaran
dc.contributor.authorSabine Chlosta
dc.contributor.authorArkendu Chatterjee
dc.contributor.authorPhilippe Armand
dc.contributor.orcid0000-0002-2112-2651
dc.contributor.orcid0000-0002-9941-2448
dc.contributor.orcid0000-0002-6728-6264
dc.contributor.orcid0000-0002-4425-7823
dc.contributor.orcid0000-0003-4247-2674
dc.contributor.orcid0000-0002-0610-7971
dc.contributor.orcid0000-0002-8566-3545
dc.contributor.orcid0000-0002-4709-0627
dc.contributor.orcid0000-0002-1326-1918
dc.contributor.orcid0000-0002-9541-8666
dc.contributor.orcid0000-0002-3949-6897
dc.contributor.orcid0000-0001-7884-6928
dc.contributor.orcid0000-0001-6098-1603
dc.date.accessioned2025-11-13T10:09:54Z
dc.date.issued2017-06-01
dc.identifier.doihttps://doi.org/10.1002/hon.2437_49
dc.identifier.endpage63
dc.identifier.issn0278-0232
dc.identifier.issueS2
dc.identifier.openalexW2622207627
dc.identifier.startpage62
dc.identifier.urihttps://hdl.handle.net/11421/3321
dc.identifier.urihttps://doi.org/10.1002/hon.2437_49
dc.identifier.volume35
dc.language.isoen
dc.relation.ispartofHematological Oncology
dc.rightsopenAccess
dc.subjectMedicine
dc.subjectPembrolizumab
dc.subjectCohort
dc.subjectInternal medicine
dc.subjectInterim analysis
dc.subjectAdverse effect
dc.subjectClinical endpoint
dc.subjectOncology
dc.subjectPopulation
dc.subjectClinical trial
dc.subjectSurgery
dc.subjectCancer
dc.subjectImmunotherapy
dc.subject.sdg3
dc.titleEfficacy and safety of pembrolizumab in relapsed/refractory primary mediastinal large B‐cell lymphoma (rrPMBCL): interim analysis of the KEYNOTE‐170 phase 2 trial
dc.typeArticle
dspace.entity.typePublication
local.authorid.openalexA5058571002

Dosyalar

Koleksiyonlar

Publications